Unit INNOVATIVE THERAPIES IN PHARMACOLOGY
- Course
- Industrial pharmacy
- Study-unit Code
- A003607
- Curriculum
- In all curricula
- Teacher
- Marco Gargaro
- Teachers
-
- Marco Gargaro
- Hours
- 32 ore - Marco Gargaro
- CFU
- 4
- Course Regulation
- Coorte 2023
- Offered
- 2023/24
- Learning activities
- Affine/integrativa
- Area
- Attività formative affini o integrative
- Academic discipline
- BIO/14
- Type of study-unit
- Opzionale (Optional)
- Type of learning activities
- Attività formativa monodisciplinare
- Language of instruction
- Italian
- Contents
- This course will provide students with a general overview of innovative immunology-based therapies currently under development for the treatment of rare diseases, oncological conditions, inflammatory disorders, and autoimmune diseases. In particular, the basic concepts of immunology necessary for understanding advanced next-generation cellular therapies will be provided.
- Reference texts
- Immunobiologia di Janeway, a cura di Kenneth Murphy, Casey Weaver, Massimo Locati, Piccin-Nuova Libraria, 2019.
- Educational objectives
- The main objective of this course is to provide students with the basic concepts for identifying and validating new immunological targets for the development of advanced and personalized pharmacological strategies.
- Prerequisites
- Successful completion of exams in General Pharmacology, Pharmacotherapy, and Experimental Pharmacology is required. Knowledge of these subjects is essential for students who wish to successfully pursue the course.
- Teaching methods
- Theoretical lessons
- Other information
- Recommended frequency
- Learning verification modality
- Oral exams
- Extended program
- This course will provide the basic concepts of immunology necessary for understanding advanced next-generation cellular therapies, including:
- Innate and adaptive immunity;
- Mechanisms of cellular communication;
- Differentiation of immune cells;
Furthermore, concepts for the development of cell-based biological drugs will be covered, such as:
- Engineered immune cells for the treatment of solid or hematological tumors (CAR-T, CAR-NK, CAR-Mac);
- Vaccines based on dendritic cells or viral vectors;
- Engineered stem cells with viral vectors for the treatment of rare diseases;
- Extracellular vesicles as carriers of biotherapeutics. - Obiettivi Agenda 2030 per lo sviluppo sostenibile
- Health and wellness